Skip to main content
Caplight Logo









BrainEver

BrainEver

Private
ParisHealthcare & Life Scienceshttps://brainever.fr/

Last Round

Grant

Jun 8, 2022

Total Funding Raised

$27.53M

Company Overview

BrainEver is a biotechnology company that develops innovative therapies for neurodegenerative diseases using homeoprotein-based treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneurodegenerative diseasehomeoprotein therapyamyotrophic lateral sclerosisALSdrug developmentbiopharmaprotein-based therapyclinical trialsParkinson's diseaseretinal diseaseneuroscience researchbiotech startupprecision medicinedrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BrainEver Comparables

Compare BrainEver with similar companies based on industry and business-model similarity.

BrainEver comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ProJenX, Inc.
80%
AcuraStem
78%
Aclipse Therapeutics
76%

BrainEver Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 8, 2022
Series ANov 23, 2020

Key People

Founding team and executive leadership

Alain Prochiantz

Co-founder & Chief Scientific Officer

Founding Team

Bernard Gilly

CEO

Executive Team

Catherine Pletan

Acting Chief Operating Officer Head of Operations

Executive Team

BrainEver Investors

Notable investors and investment history

BrainEver investors
InvestorRounds
European Innovation Council FundGrant
Turenne GroupeSeries A
iBionextSeries A
BpifranceSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 22, 2026

    Grew 29% QoQ, from 21 to 27 employees.

  • Jan 1, 2026

    Monthly visitors grew 38% MoM.

BrainEver Filings

Explore SEC and related filing metadata, where available.

BrainEver filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BrainEver's valuation, stock price, and market status.

Is BrainEver a public or private company?

BrainEver is a private company.

What is the current stock price of BrainEver?

BrainEver is a private company with no public stock price. No recent secondary market data is available.

How much is BrainEver worth (valuation)?

Valuation information for BrainEver is not publicly available.

Can I buy BrainEver stock?

BrainEver shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BrainEver's last funding round?

BrainEver's most recent funding round was Grant on June 8, 2022.

Who are the main investors in BrainEver?

Key investors in BrainEver include European Innovation Council.

Will BrainEver IPO soon?

No public IPO plans have been announced for BrainEver.

How can I track BrainEver secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BrainEver's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range20
Year Founded2016
Last FundingJun 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?